Study survival percentages grouped by year.
| Survival percentages | Author | EFS ± SD (95% CI) | PFS ± SD (95% CI) | OS ± SD (95% CI) |
|---|---|---|---|---|
| 3-year survival percentages | Dufour et al., 2021 [16] | NR | 78 (65–88) | 84 (72–92) |
| Okada et al., 2020 [22] | NR | SR: 90.5 ± 5.2HR: 100 | SR: 93.9 ± 4.2HR: 100 | |
| Packer et al., 1994 [23] | 90 ± 4 | 90 ± 4 | NR | |
| Rieken et al., 2011 [26] | NR | LPFS: 73DPFS: 87 | Overall: 84 | |
| Tian et al., 2020 [30] | NR | NR | PF: 59.1TB: 70 | |
| 4-year survival percentages | Ashley et al., 2012 [13] | 50 ± 6 | NR | 69 ± 5.5 |
| 5-year survival percentages | Allen et al., 2009 [12] | NR | 43 ± 5 | 52 ± 5 |
| Gajjar et al., 2006 [5] | SR: 83 (73–93) (p = 0.046)HR: 70 (55–85) | NR | SR: 85 (75–94) (p = 0.04)HR: 70 (54–84) | |
| Jakacki et al., 2012 [18] | NR | Regimen A: 71 ± 11Regimen B: 59 ± 10 | Regimen A: 82 ± 9Regimen B: 68 ± 10 | |
| Lannering et al., 2012 [19] | Overall: 82 ± 2STRT: 77 ± 4HFRT: 78 ± 4 | NR | STRT: 87 ± 3HFRT: 85 ± 3 | |
| Lee et al., 2020 [20] | 71.1 ± 8 | NR | 73.2 ± 7.9 | |
| Massimino et al., 2012 [21] | Overall: 48 ± 6Patients ≤ 10 years: 38 ± 8Patients > 10 years: 59 ± 8 | NR | Overall: 56 ± 6Patients ≤ 10 years: 41 ± 8Patients > 10 years: 73 ± 8 | |
| Merchant et al., 2008 [8] | 83 ± 5.3 | NR | 94.7 ± 3.4 | |
| Michalski et al., 2021 [7] | IFRT: 82.5 (77.2–87.8)PFRT: 80.5 (75.2–85.8)LDCSI: 71.4 (62.8–80) (p = 0.028)SDCSI: 82.9 (75.6–90.2) | NR | IFRT: 84.6 (79.7–89.5)PFRT: 85.2 (80.5–89.9)LDCSI: 77.5 (69.7–85.3) (p = 0.049)SDCSI: 85.6 ± 3.5 (78.7–92.5) | |
| Packer et al., 1994 [23] | Overall: 83 ± 6 | Overall: 85 ± 6 | Overall: 85 ± 6SDCSI: 83 ± 6LDCSI: 83 ± 20 | |
| Packer et al., 2006 [24] | Overall: 81 ± 2.1Regimen A: 82 ± 2.8Regimen B: 80 ± 3.1 | NR | Overall: 86 ± 1.9Regimen A: 87 ± 2.6Regimen B: 85 ± 2.8 | |
| Pezzotta et al., 1996 [25] | Overall: 47.4SR: 27.3HR: 55.6 | 55.26 | NR | |
| Rieken et al., 2011 [26] | NR | LPFS: 62DPFS: 77 | Overall: 73 | |
| Sirachainan et al., 2018 [28] | NR | 41.8 ± 12.2 | 60 ± 11.2 | |
| Sung et al., 2013 [29] | 70 ± 10.3 | NR | 73.9 ±10.2 | |
| Tian et al., 2020 [30] | NR | NR | PF: 50TB: 58.3 | |
| Wahba et al., 2013. [31] | 79 | NR | 85 | |
| Yasuda et al., 2008 [32] | 82 (59–100) | Patients ≤ 5 years: 75 (45–100)Patients > 5 years: 88 (65–100) | Overall: 82 (59–100)Patients ≤ 5 years: 75 (45–100)Patients > 5 years: 88 (65–100) | |
| 6-year survival percentages | Carrie et al., 2009 [14] | 95 (62–87) | 75 | 78 (66–90) |
| 9-year survival percentages | Packer et al., 1994 [23] | 72 ± 13 | NR | NR |
| 10-year survival percentages | Christopherson et al., 2014 [15] | 67 | 71 | 67 |
| Gupta et al., 2022 [17] | NR | 63.2 (52.1–74.4) | 74.1 (63.9–84.1) | |
| Massimino et al., 2012 [21] | 42.6 ± 6 | NR | 46 ± 6 | |
| Rieken et al., 2011 [26] | NR | LPFS: 43DPFS: 71 | Overall: 53 | |
| Rutkowski et al., 2009 [27] | NR | HIT-SKK’87: 48.3 ± 9.3HIT-SKK’92: 55.2 ± 9.2 | HIT-SKK’87: 55.2 ± 9.3HIT-SKK’92: 63.6 ± 7.6 | |
| Sirachainan et al., 2018 [28] | NR | NR | 48 ± 14 |
CI: confidence interval; DPFS: distal progression-free survival; EFS: event-free survival; HFRT: hyperfractionated radiation therapy; HIT-SKK’87 and ’92: (Brain Tumor Radiotherapy for Infants and Toddlers with Medulloblastoma) 1987 and 1992; HR: high risk; IFRT: involved field radiation therapy; LDCSI: low-dose craniospinal irradiation; LPFS: local progression-free survival; NR: not reported; OS: overall survival; PF: posterior fossa; PFRT: posterior fossa radiation therapy; PFS: progression-free survival; SD: standard deviation; SDCSI: standard-dose craniospinal irradiation; SR: standard risk; STRT: standard radiation therapy; TB: tumor bed. 95% CI noted in parenthesis and SD documented if reported.